Article Information
vol. 58 no. 1
PubMed
Published By
Print ISSN
Online ISSN
History
- Received May 1, 2020
- Accepted December 9, 2020
- Published online July 8, 2021.
Article Versions
- previous version (January 8, 2021 - 02:13).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©ERS 2021 This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.
Author Information
- Imre Noth1,
- Vincent Cottin2,
- Nazia Chaudhuri3,
- Tamera J. Corte4,5,
- Kerri A. Johannson6,
- Marlies Wijsenbeek7,
- Stephane Jouneau8,
- Andreas Michael9,
- Manuel Quaresma10,
- Klaus B. Rohr10,
- Anne-Marie Russell11,
- Susanne Stowasser10 and
- Toby M. Maher12,13,14 on behalf of the INMARK trial investigators
- 1Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA
- 2National Reference Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, Lyon, France
- 3North West Interstitial Lung Disease Unit, Manchester University NHS Foundation Trust, Manchester, UK
- 4Royal Prince Alfred Hospital, Camperdown, Australia
- 5University of Sydney, Sydney, Australia
- 6Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
- 7Dept of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
- 8Hôpital Pontchaillou – CHU de Rennes, IRSET UMR 1085, Université de Rennes 1, Rennes, France
- 9Syneos Health, Farnborough, UK
- 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
- 11College of Medicine and Health, University of Exeter, Exeter, UK
- 12National Heart and Lung Institute, Imperial College London, London, UK
- 13National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK
- 14Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
- Toby M. Maher (t.maher{at}rbht.nhs.uk)
Funding
Boehringer Ingelheim